Regorafenib drug Edit

«Regorafenib (BAY 73-4506, commercial name Stivarga) is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had 2 US approvals for advanced cancer(wikipedia)

  • Has Subnodes:

 
Modified 3 weeks ago on Dec 28, 2019
MoreVitaminovPRO ranked added it 7 months ago on Jun 18, 2019